The effects of nerve growth factor (3(-NGF) and ganglioside GM1 on forebrain cholinergic neurons were examined in vivo and in vitro. Following unilateral decortication of rats, GM1 (5 mg/kg per day) administered intracerebroventricularly could protect forebrain cholinergic neurons of the nucleus basalis magnocellularis from retrograde degeneration in a manner comparable to P-NGF. Administered in combination with (-NGF, GM1 produced a significant increase in choline acetyltransferase activity in the nucleus basalis magnocellularis and remaining cortex ipsilateral to the lesion. Concentrations of GM1 that were ineffective when administered alone in this lesion model, when given with .3-NGF, potentiated (i-NGF effects in both of the above brain areas. In dissociated septal cells in vitro, an increase in choline acetyltransferase activity was noted at fi-NGF concentrations as low as 0
potentiated (i-NGF effects in both of the above brain areas. In dissociated septal cells in vitro, an increase in choline acetyltransferase activity was noted at fi-NGF concentrations as low as 0.1 pM and reached a plateau at 1 nM. A moderate (up to 35%) stimulation of choline acetyltransferase activity was observed with 10 ,uM GM1. The application of 13-NGF in combination with 10 ,uM GM1 or 0.1 ,uM GM1, a concentration that is ineffective in these cultures, produced a much greater increase in choline acetyltransferase activity than did 18-NGF alone. These observations support the idea that exogenously applied gangliosides can elicit trophic responses in cholinergic neurons of the central nervous system. That GM1 increases and even potentiates 13-NGF effects suggests that some of the trophic actions of this compound may be mediated through endogenous trophic factors.
Nerve growth factor ,3 (P3-NGF) can be considered the prototype for substances exerting in vivo and in vitro trophic effects on defined cells of the nervous system (1) . In addition to its peripheral actions, j3-NGF acts on subsets of centrally located neurons (2, 3) . Central forebrain cholinergic neurons contain B3-NGF binding sites, and their terminal targets produce the trophic peptide, which can be transported retrogradely to cell bodies of these cholinergic neurons (4) . In the adult, these cholinergic neurons respond to exogenous ,B-NGF after partial or total damage of the septal-hippocampal connections (5) (6) (7) . In addition, /3-NGF has been found to affect forebrain cholinergic neurons in vitro (8, 9) .
Sialogangliosides, in particular GM1, exert trophic-like activity, both in vivo and in vitro, and resemble "bona fide" trophic factors in many ways (for review, see ref. 10 ). When applied in vivo, they promote the anterograde regeneration of acetylcholinesterase-reactive fibers in the hippocampus after partial fimbria transections (11) . Administration of GM1 also prevents the retrograde cell shrinkage of cholinergic neurons of the nucleus basalis magnocellularis (NBM) that follows cortical infarction (12) , as well as cell death in the medial septum after unilateral hippocampal ablation (13) . These findings have prompted us to investigate the possible in vivo and in vitro interactions between a selective and a specific trophic factor (,B-NGF) and a biological substance (GM1) whose apparent trophic activity is less well defined. Our preliminary observations in the in vivo model (14) and the results presented here strongly suggest that the ganglioside GM1 has an enabling or potentiating effect on P-NGFmediated responses in central cholinergic neurons.
MATERIAL AND METHODS
Cortical Lesions and Drug Treatment. Male Wistar rats (Charles River Breeding Laboratories, 300-350 g) were used in these experiments and were subjected to a unilateral left-side cortical devascularizing lesion as described (15) . The surgical procedure produced a limited, well-defined infarction of the neocortex without affecting underlying brain structures (15) .
A group of lesioned rats (n = 5) received GM1 (0. alone or in combination with GM1 (0.5 or 5 mg/kg per day) in the same manner. A group of lesioned rats (n = 6) received physiological saline (0.9% NaCl) containing 0.1% bovine serum albumin; Sigma), and rats that had not undergone surgery (n = 6) served as controls. Animals were decapitated 30 days after the surgical procedure (i.e., 23 days after treatment with f3-NGF and/or GM1 ceased). Discrete brain areas were microdissected from fresh tissue slices as described (15) .
Biochemical Analysis of Microdissected Tissue. Microdissected tissues were kept frozen at -80°C until required. Choline acetyltransferase (ChAT) activity was determined by a radiometric assay described by Fonnum (17) , and protein content was determined by the Bradford method (18) .
Immunohistochemical Analysis of Brain Tissue. Three additional rats from each group were anesthetized and perfused as described (19) . Sections (50 ,um) of the entire NBM were obtained from frozen brain tissue blocks by using a sliding microtome (Reichert). Sections were then processed freefloating for ChAT immunocytochemistry (19) .
Cell Culture. The septal area was dissected from brain of day-17 embryonic rat fetus (Sprague-Dawley) as described by Dunnett et al. (20) . Dissociated septal cells were prepared by a modification of a published method (21) . Viable final cell density of 0.6 x 106 viable cells per ml and seeded (1 ml of cell suspension per well) on poly(L-lysine) (Sigma)-coated culture wells (16 mm diameter) in 24-well plates (Falcon). One rat embryo yielded on average 0.5-0.75 x 106 viable septal cells. Exposure of the cells to either 13-NGF or GM1 began immediately after seeding. Cultures were maintained at 370C in a humidified incubator in a 95% air/5% CO2 atmosphere. The cells were inspected regularly and medium was replenished every 3 days. Data were analyzed by analysis of variance (ANOVA) and/or two-tailed t test.
Biochemical Determinations of Tissue Culture Preparations. The cells in culture were washed free of medium with Ca2+/Mg2+-free phosphate-buffered saline (PBS, pH 7.4), collected in a total volume of 100 gl of homogenization buffer (10 mM EDTA/0.5% Triton X-100, pH 7.4), and homogenized on ice in a glass homogenizer. Aliquots of the homogenate were taken for determination of ChAT activity (17) Fig. 1 a and b) . As previously reported (15) , when compared with the control group, no significant changes in ChAT activity were found in any other microdissected brain areas (data not shown).
The i.c.v. administration of 13-NGF (12 ,tg per day), for 7 days from the onset of the lesion, prevented a decrease in ChAT activity in the NBM after partial cortical infarction. The magnitude of this protective effect was shown to be comparable to that obtained with the i.c.v. administration of GM1 alone (5 mg/kg per day) ( Table 1 , experiment A). The combined administration of P-NGF and GM1 in the partially decorticated animals increased ChAT activity in the NBM, ipsilateral to the lesion, above control levels. Immunocytochemical analysis revealed not only full protection of the cholinergic neurons from retrograde cell shrinkage and loss of dendritic extensions but also an apparent increase in the number of ChAT-immunoreactive processes in the neuropil (Fig. lc) .
In this series of experiments ChAT activity in the remaining cortex of the lesioned animals was found to be similar to that of the unlesioned side. Furthermore, treatment with ,B-NGF or GM1 alone increased ChAT activity ofthe lesioned side over that of control. A more noticeable cooperativity between these two factors was observed in the remaining neocortex ipsilateral to the lesion, where the combined treatment brought ChAT activity to 237% of control values (Table 1) .
In cortically lesioned animals treated with low doses of GM1 (0.5 mg/kg per day, i.c.v., 7 days), a significant decrease (32% of control values) in ChAT activity was observed in the NBM ipsilateral to the lesion (Table 1 , experiment B). However, if these subthreshold amounts of ganglioside were administered concurrently with effective doses of 8-NGF to lesioned animals, a significant increase -.4pp~~~. (21%) in ChAT activity was observed in the area of the affected forebrain cholinergic neurons. Even more remarkable were the changes observed in ChAT activity in the ipsilateral cortex of the lesioned animals after simultaneous i.c.v. administration of subthreshold amounts of GM1 and effective doses of 3-NGF. While this low dosage of GM1 per se did not alter ChAT activity in the remaining ipsilateral cortex, in combination with f3-NGF it produced a marked increase of the ChAT enzymatic activity.
In Vitro Studies. Dissociated septal cells in culture represent a mixed neuronal-glial cell population as determined immunocytochemically with the use of antiserum to glial fibrillary acidic protein and antiserum to neurofilament pro- tein (data not shown). The presence of ChAT-immunoreactive neurons in this culture system was confirmed as well ( Fig. 2) . Although immunoreactive sites for the 3-NGF receptor were found on cells with neuronal appearance (Fig.  2) , a number of non-neuronal cells were found to possess these receptors. Upon exposure of these cells in culture to either p-NGF or GM1, ChAT activity was subject to modulation. ChAT activity in the septal cell cultures was dramatically increased after a 7-day exposure to exogenous /3-NGF.
As observed by Hatanaka and Tsukui (9) this increase in enzyme activity was dose-related. In our experiments, the increase in ChAT activity was detectable at f3-NGF concentrations as low as 0.1 pM and was maximal at 1 nM. Exposure of the cells to nanomolar concentrations of ,B-NGF increased ChAT enzymatic activity to 200% of control levels (Fig. 3) . GM1, on the other hand, produced a less dramatic increase in ChAT activity. Enzyme induction was detected only when cells were exposed to 10 ,tM GM1 and was increased over control by some 15-30%. Lower concentrations of GM1 (e.g., 0.1 ,uM) were found to be ineffective when applied alone to these cultures (Fig. 4) . ChAT enzymatic activity that was significantly greater than that obtained with j3-NGF alone. This potentiating effect of GM1 was more dramatic when GM1 was applied in combination with 0.1 pM B-NGF. We found that even 0.1 ,uM GM1, which was ineffective when applied alone, potentiated the ,-NGF-induced increase in ChAT activity (Figs. 3 and 4) . DISCUSSION The trophic effects of p-NGF on central and peripheral neurons are in all likelihood receptor-mediated. Although there is still no definite information on the cellular and molecular events that take place following the interaction of P-NGF with its receptor, several mechanisms have been postulated (for review, see ref. 24 ). The interaction of the ganglioside with endogenous trophic factors, and with ,B-NGF in particular, could take place at any level. Nevertheless, it is likely that this interaction occurs at the level of the cell membrane where GM1 is incorporated (25) . In this regard, it is interesting that immobilized GM1 is capable of binding P-NGF with low affinity (26) . Thus, gangliosides could provide additional binding sites for growth factors or, on the other hand, may modify the growth factor receptor state, as is the case for the ganglioside GD2 and the vitronectin receptor (27) . Certain conditions are required for gangliosides to show a trophic effect in vivo or in vitro. These have been referred to as "permissive conditions" for the in vivo effects (19) or a "window of opportunity" for the in vitro effects.t It is conceivable that under certain conditions the availability of endogenous trophic factors is affected, and consequently the ability of cells to respond to these factors is influenced. In the in vivo experimental model, the early initiation ofganglioside treatment is essential (19) . This is in agreement with the evidence that, in response to injury, the brain produces low amounts of endogenous trophic factors immediately after the insult (e.g., ref. 28). Therefore, in instances of extensive neural lesions, a situation of extreme vulnerability might arise. In such a case, irreversible anterograde and retrograde cellular damage would occur. In the case of central cholinergic neurons, retrograde degenerative changes can be in part reversed by the timely administration of P-NGF (5) (6) (7) . In view of the above, it can be proposed that in the present in vivo situation the administration of gangliosides prevents anterograde and retrograde neuronal degeneration by potentiating the action of the limited quantity of endogenous trophic factors produced in the first few days subsequent to the lesion. The difficulties encountered in rescuing cholinergic neurons by administration of exogenous gangliosides in aged rats (19) could be explained in the same way, since aging is accompanied by an apparent loss of f3-NGF receptors (29) and a diminished production of endogenous factors after injury (30 (33) reported that gangliosides did not potentiate the effects of P-NGF on septal cells in culture, their experiments differed from ours, as they employed a mixture of gangliosides rather than pure GM1 and a single, high concentration of f-NGF. We have observed that the synergism between GM1 and P-NGF occurs at submaximal concentrations of P-NGF. However, the molecular mechanisms underlying these interactions have not yet been properly examined. Nevertheless, it is possible that the contribution of glial cells is important both in vivo and in vitro. There is evidence that p-NGF is produced by glial cells (34) . In vivo, neural damage results in reactive gliosis, a phenomenon that may contribute to increased availability of endogenous trophic factors.
Validation of the ganglioside-trophic factor cooperativity hypothesis will require further investigations ofthe molecular mechanisms underlying their interactions in the central and peripheral nervous systems. There is already evidence of the cooperativity of P-NGF and gangliosides in the peripheral nervous system (35) . The investigation of the interaction of gangliosides with j3-NGF and other trophic factors may provide valuable insight for the establishment of therapeutic regimes in neurodegenerative diseases.
